Current Events

Scientists routinely use cell lines as healthy and diseased tissue models within drug development. They are easy to maintain, a stable platform and relatively inexpensive. However, they often do not reflect what is physiologically relevant in vivo. This is where primary cells may be a more advantageous choice for complex physiological disease and now an integral platform within Immuno-Oncology Research. << less

Scientists routinely use cell lines as healthy and diseased tissue models within drug development. They are easy to maintain, a stable platform and relatively inexpensive. However, they often do not reflect what is physiologically relevant in vivo. This is where primary cells may be a more advantageous more >>

3rd Annual Pharma Pricing, Reimbursement & Market Access 2020
02nd - 03rd December 2020, Virtual Conference (Time Zone - EST)
This conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.
Please contact KAVITHA on E-mail - kavitha@virtueinsight.co.in
FEATURES OF OUR VIRTUAL CONCFERENCE:
This virtual conference is a platform to connect, engage and network with industry professionals & solution providers while saving time and ensures enhancement of knowledge at ease.
 Attend all sessions through this webinar (Solo presentations and interactive panel discussions)
 Delegates can see the other delegates and can network with them at the networking lounge at any time during the conference day.
 Delegates can see the exhibitors in their respective booths and they can visit the booths and have a private chat with the exhibitors.
CONFERENCE DELEGATE REGISTRATION:
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.
Early Bird Discount Price:
1 Delegate @ US$ 350 + VAT (Valid until 12th October 2020)
3 Delegates @ US$ 900 + VAT (Valid until 12th October 2020)
Standard Price:
1 Delegate @ US$ 499 + VAT (Valid from 13th October2020)
Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to kavitha@virtueinsight.co.in
KEY SPEAKERS:
• ROBYN BENT, Director, CDER Patient, Focused Drug Development Program, FDA
• ROBERT POPOVIAN, Vice President, US Government Relations, Pfizer
• BEHZAD MAHDAVI, VP Strategic Innovation & Alliances, Lonza
• WENDY ERLER, VP, Patient Experience / STAR & Patient Advocacy, Alexion Pharmaceuticals
• SARA YIN, Senior Director of Access Marketing, Epizyme
• JENNIFER WONG, Senior Director, Real World Evidence, Strategy & Alliances, AstraZeneca
• MARTIN ROST, Senior Director, Market Access (Global), Pfizer
• TIMOTHY LENEHAN, Senior Director - Global Head of Pricing and Payer Access Solutions, Biogen
• MATTHEW HURLBURT, Global Access Transformation Lead, Pfizer
• RICHARD LINER, Senior Compliance Counsel, Bayer
• ALEEN HOSDAGHIAN, Sr. Director of Marketing, Sun Pharma
• TIM HERMES, VP Market Access, Trade & Patient Services, Aurinia Pharmaceuticals
• CHARLES MAKIN, Global Head, Real World Evidence Strategy, Biogen
• ALAN POLNARIEV, Medical Science Liaison, Oncology/Urology Gastroenterology, Ferring Pharmaceuticals
• GARY ELLEXSON, VP Corporate Accounts, Supernus Pharmaceuticals
• AMY PETERPAUL, Executive Director of Pricing, Contracting & Value Strategies, Helsinn
• SAM MURPHY, VP and Head of International BD, Shenzhen Salubris Pharmaceuticals
• ANKA EHRHARDT, Science Director, CHDI Foundation
• BOXIONG TANG, Sr. Director, BeiGene
• HEATHER LEIGH FLANNERY, Global Lead, ConsenSys Health
• MICHAEL THOMPSON, President & CEO, National Alliance of Healthcare Purchaser Coalitions
• SHANTHY KRISHNARAJAH, Senior Director, Global Health Economics Reimbursement Strategy, Seqirus
• TIM EPPLE, Principal, Financial Services, Avalere Health
• SUSAN THORNTON, CEO, Cutaneous Lymphoma Foundation
• KEVIN MAYO, Managing Partner, Value Genome
• EVERETT CROSLAND, VP of Market Access & Reimbursement, AppliedVR
• MELVA COVINGTON, Senior Director, EVERSANA, Health Economics and Outcomes Research
• REED STEPHENS, Partner-In-Charge Washington, D.C. Health Industry Advisory Group, McDermott Will & Emery
• STACEY L. WORTHY, Partner, DCBA Law & Policy
• SAIRA SULTAN, President & CEO, Connect 4 Strategies
Get more from the event, with a broader scope bringing the whole communications value chain together.
<< less

3rd Annual Pharma Pricing, Reimbursement & Market Access 2020
02nd - 03rd December 2020, Virtual Conference (Time Zone - EST)
This conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current more >>

The Alderley Park Oncology Development Programme

22nd Pharmacovigilance 2020
“Latest developments in pharmacovigilance, drug safety and RMP”
09th - 10th December 2020, Virtual Conference (Time Zone - EST)
Our event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Get more from the event, with a broader scope bringing the whole communications value chain together. This event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Get more from the event, with a broader scope bringing the whole communications value chain together. Please contact KAVITHA on E-mail - kavitha@virtueinsight.co.in or Call - +44-20 3509 3779
DELEGATE REGISTRATION:
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.
EARLY BIRD PRICING
1 Delegate @ US$399 (Valid Till 16th November 2020)
3 Delegates@ US$1,099 (Valid Till 16th November 2020)
STANDARD PRICING
1 Delegate @ US$599 (From 17th November 2020)
3 Delegate @ US$1,499 (From 17th November 2020)
Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to kavitha@virtueinsight.co.in or Call - +44-20 3509 3779
KEY SPEAKERS:
• SONGLIN XUE, Executive Vice President and Global Head of Pharmacovigilance, Astellas Pharmaceuticals
• DIANE E. BECK, Vice President & Head of PV Affiliate Relations Global Patient Safety Evaluation, Takeda Pharmaceuticals
• SHARON REID, Director, Risk Management Product Lead, Pfizer
• BRUNO MENDEZ, VP Global Quality Head Pharmacovigilance, Sanofi
• WILLIAM WANG, Executive Director, Clinical Safety Statistics, Merck
• KHAUDEJA BANO, Executive Medical Director, Combination Product Safety Head, Amgen
• SHAUN COMFORT, Principal Scientific Enablement Director, Roche – Genentech
• DEEPA VENKATARAMAN, Senior Director, Patient Safety Operations, Abbvie
• SHEETAL KHEDKAR, Medical Safety Officer- Oncology, Global Medical Safety, Janssen, Pharmaceutical Companies of Johnson and Johnson
• TANJA PETERS, Head Global Patient Safety Neurology & Immunology, Merck KGaA
• AMGAD SHEBL, Director, Global Clinical Safety & PV / Clinical R&D, CSL Behring
• RICKY RUDRARAJU, Sr. Principal Scientist - Global Patient Safety Evaluation, Takeda Oncology
• RAJ BHOGAL, Sr. Director, R&D Audits & Inspections, Jazz Pharmaceuticals
• MARIA ESTRADA, Medical Director, Pharmacovigilance, Deciphera Pharmaceuticals
• SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda
• TEODORA DOHERTY, Global Medical Safety (GMS), Medical Safety Officer, Janssen Research & Development
• SANDRINE VALIERE, Global PV Audit/Inspection Readiness Head, Sanofi
• JAYLAXMI NALAWADE, Associate Director - Pharmacovigilance & REMS, Lupin
• TOYIN ADEWOLE, Assistant Director, Drug Safety, Supernus Pharmaceuticals
• HUMAIRA QURESHI, President, Bioclinica
• MIRCEA CIUCA, Global Therapeutic Area Head - Global Clinical Safety & PV, CSL Behring
• DAVID HUTCHINSON, Founder and Owner, Brookwood Gobal
• HEIDE CUNNING, US Pharmacovigilance Officer-Safety Services Operations, Janssen Pharmaceuticals
• KATARINA ILLIC, Senior Clinical Pharmacology Medical Leader, Takeda Pharmaceuticals
• ANKA G. EHRHARD, Director, Clinical Research, CHDI Foundation
• ADEDEJI ADEFUYE, Head, Medical Safety, Rare Diseases & PDT and Head, CoE for Medical Device Safety, Takeda
• OYINKANSOLA ODEBO, Assistant Director, Drug Safety Clinical Research, Supernus Pharmaceuticals
• BEN LOCWIN, Senior VP, Quality, Lumicell
Plus more joining soon
FOCUSES ON:
• Market analysis – Pharmacovigilance in 2022 - future horizons and efficiencies
• Regulations, Legal & Brexit Implications for the pharmacovigilance Industry
• Outsourcing in Pharmacovigilance- Best Practices, Challenges and key consideration
• New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT, Blockchain & Big Data)
• PV Audit & Inspections – Knowing what is to be done
• RWE & RWD
• Documentation (RMPs, PSURs, PADERs, PBRERs)
• Quality, Safety and Signal Detection - Future of 2020
• Medical devices – Increasing safety perspective
• Case studies from various countries on the PV frameworks around the world
• Patient centric approach to help improve patient safety
• The developing regulatory framework in advanced and developing markets – EU, USA & ROW
• Be part of a major networking opportunity
Get more from the event, with a broader scope bringing the whole communications value chain together.
<< less

22nd Pharmacovigilance 2020
“Latest developments in pharmacovigilance, drug safety and RMP”
09th - 10th December 2020, Virtual Conference (Time Zone - EST)
Our event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key more >>

23rd Pharmacovigilance 2020
“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”
16th December 2020, Virtual Conference (Time Zone - IST)
Our conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. This year’s conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expectedness of serious adverse reactions during clinical development. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full-day will be devoted to the development, implementation, and assessment of risk management strategies for drugs approved in multiple regions. Please contact KAVITHA on E-mail - kavitha@virtueinsight.co.in or Call - +91 44 24762472
DELEGATE REGISTRATION:
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.
• Early Bird Discounted Price (Vaild till 15th November 2020) - (INR 7,000 + GST (18%) per delegate)
• Standard Price (Valid from 16th November 2020) - (INR 10,000 + GST (18%) per delegate)
• For Bulk Booking of More Than 5 Delegates – Please let us know your interests.
Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to kavitha@virtueinsight.co.in or Call - +91 44 24762472
KEY SPEAKERS:
We are happy to release the event brochure with the first set of confirmed key speakers, with more to follow soon
• BABITA KIRODIAN, Country Pharmacovigilance Lead, Amgen
• S.SALAVADI EASWARAN, Academic Dean, Biocon Academy
• ARUN BHATT, Consultant – Clinical Research & Development
• OMPRAKASH S. SADHWANI, Former Joint Commissioner and controlling Authority, FDA (Maharashtra state)
• INDU NAMBIAR, Head Pharmacovigilance, Boehringer Ingelheim
• S.R.SALUNKHE, Former Assistant commissioner, FDA Maharashtra
• MANOJ SWAMINATHAN, Chief Manager / Head - Global Pharmacovigilance Center, Piramal
• JAMAL BAIG, Country Head- Pharmacovigilance, Merck Sharp & Dohme
• RANJIT BARSHIKAR, QbD / CGMP Consulting, Member Editorial Board Journal of Generic Medicines, England
• PAVAN BADALE, Head- PV Process Excellence, Safety case Management, Novartis
• DHANARAJ E, Pharmacovigilance Lead, Biocon
• JYOTSNA PATWARDHAN, Head Development QA, Novartis
• SAKHARAM GARALE, Head South-East Asia Operations ACMA & Managing Partner, RENOVARE Healthcare Solutions
• KAVYA KADAM, Consultant Global Clinical Trials
Plus more joining soon
FEATURES OF OUR VIRTUAL CONFERENCE:
This virtual conference is a platform to connect, engage and network with industry professionals & solution providers while saving time and ensures enhancement of knowledge at ease.
• Attend all sessions through this webinar (Solo presentations and interactive panel discussions)
• Delegates can see the other delegates and can network with them at the networking lounge at any time during the conference day.
• Delegates can see the exhibitors in their respective booths and they can visit the booths and have a private chat with the exhibitors.
Get more from the event, with a broader scope bringing the whole communications value chain together.
<< less

23rd Pharmacovigilance 2020
“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”
16th December 2020, Virtual Conference (Time Zone - IST)
Our conference provides the foundation for strong strategic planning and practical decision-making more >>

The 2020 ELRIG Research & Innovation conference will discuss how the most promising new biology is being identified and explore emerging technologies and innovations to enable this science to be translated into successful therapeutics. The four scientific sessions will address different aspects of innovation in biology and discovery technologies as we move into a new decade

In accordance with current government guidelines on the COVID-19 pandemic, the third CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held on 23rd and 24th March 2021 as a virtual event. Genome Engineering, including zinc-finger nucleases, TALENs and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus. The scientific program for this CRISPR in Drug Discovery meeting will include:

Large-scale CRISPR functional genomics studies for drug target identification and validation
Application of genome engineering in developing biological models of disease from single cells through to complex in vitro tissue systems and in vivo models
Cutting edge CRISPR genome engineering technologies and their emerging applications
A perspective from technology leaders toward the future therapeutic applications of genome engineering
We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech and CRO’s online to hear talks given by speakers at the cutting edge of genome engineering, network at the virtual exhibition and gain strategic insights into solutions for increasing the success of drug discovery and development. << less

In accordance with current government guidelines on the COVID-19 pandemic, the third CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held on 23rd and 24th March 2021 as a virtual event. Genome Engineering, including zinc-finger nucleases, TALENs and most recently CRISPR/Cas9, more >>

18th of May 2021 at the AstraZeneca R&D site in Gothenburg. This interactive 2-day conference will host world leading scientists from academia and industry to discuss current and future perspectives of Cell and Gene Therapies.

Cell and gene therapies are rapidly evolving at a fast pace, revealing many new and exciting therapeutic opportunities not previously amenable to drug discovery. We aim to bring together scientists from academia, pharma, biotech, and CRO’s to engage with speakers at the cutting edge of developing and applying cell and gene therapies.

The event will help participants develop a better understanding of the field and provide networking opportunities with a range of key experts. Our aim is to create an open and inspiring environment that will foster discussions and the identification of opportunities for collaboration with a scientific program developed around three key focus areas:

• Cell based therapies across disease areas
• Recent advances in cancer gene therapies
• Therapies for genetic conditions

There will be numerous opportunities to network with scientists and researchers from the pharmaceutical, academic and vendor communities throughout the 2-day conference. The program also includes poster viewing sessions, a poster spotlight presentation opportunity for select posters, vendor exhibition, speaker’s dinner and tour of the Amazing Journey at AstraZeneca. << less

18th of May 2021 at the AstraZeneca R&D site in Gothenburg. This interactive 2-day conference will host world leading scientists from academia and industry to discuss current and future perspectives of Cell and Gene Therapies.

Cell and gene therapies are rapidly evolving at a fast pace, revealing more >>

The global need for effective medicines is increasing, whilst the biology underlying new drug concepts is becoming increasingly complex. This meeting will outline how our research community is rising to address these challenges by following the early life cycle of new medicine concepts through 3 critical stages: 1) Identifying your target. 2) Drugging your target. 3) Gaining clinical insights. These session themes will run sequentially and blend the most exciting science from early career researchers, commercial organisations and key academic, clinical and industry leaders in the field. In addition, an interactive panel discussion will provide the opportunity to share perspectives on some of the most current and innovative routes though which to translate scientific ideas into impactful therapies. Topics in scope for this scientific program will include:
Target Identification & Validation
• Disease-centric biology insights & dealing with increasingly complex target biology
• Leveraging emerging platform technologies
• Deconvoluting target hit lists
Drugging your target
• How new drug formats are changing drug discovery
• New concepts in pharmacology – poly-pharmacology, cellular kinetics etc
• New models of collaborative drug discovery (panel discussion topic)
Clinical insights
• Experimental medicine studies with proprietary and/or essential medicines
• Examples of successful clinical translation of new medicine concepts
• Bringing patient data insights into the discovery pipeline
Through this meeting, we aim to bring together the research community working in the field of new medicine creation with interests in developing their translational research ideas and applying novel technologies and means of collaboration to address critical clinical needs. Join scientists from academia, pharma, biotech and CRO’s either in person or online to hear talks given by speakers at the cutting edge of their field and gain strategic insights into solutions for increasing the success of your therapeutic ideas.
<< less

The global need for effective medicines is increasing, whilst the biology underlying new drug concepts is becoming increasingly complex. This meeting will outline how our research community is rising to address these challenges by following the early life cycle of new medicine concepts through 3 critical more >>

The fourth ELRIG meeting on Advances in Cell Based Profiling in Drug Discovery will be held on the 9th and 10th of November 2021 at the AstraZeneca R&D premises in Gothenburg. This interactive 2-day event will host leading scientists from academia and industry to discuss current and future formats for cell based assays. Following on from our last meeting in 2019 this bi-annual meeting will also this time be accompanied by a satellite meeting on Chemical Biology on November 11th, organized by key academic infrastructures in the Nordic countries. Our aim is to create an open and inspiring environment for networking between biologists and chemists, working towards a common view on expectations from our cell assays and their use for target identification, target validation and compound profiling purposes. << less

The fourth ELRIG meeting on Advances in Cell Based Profiling in Drug Discovery will be held on the 9th and 10th of November 2021 at the AstraZeneca R&D premises in Gothenburg. This interactive 2-day event will host leading scientists from academia and industry to discuss current and future formats for more >>

Pharmaceutical Flow Cytometry & Imaging 2021
The 7th biennial Pharmaceutical Flow Cytometry and Imaging meeting will be held at GlaxoSmithKline, Stevenage, UK. Flow cytometry and imaging are two powerful technology platforms that enable high-content analysis of physiologically-relevant cell systems and pre-clinical and clinical biomarkers. Since our first meeting in 2008, we have seen the technology develop and the applications widen across many areas of industrial and academic drug discovery and development.
This meeting will focus on the application of Flow Cytometry and Imaging to illuminate biology from the single cell to the patient. The scientific program for this meeting is:
Translational Flow Cytometry and Imaging in Drug Discovery and Development: Application of technology in biological models from the microscale and single cell through to complex in-vitro tissue systems and the clinic.
Novel and Emerging Technologies: Next generation instrumentation, and probe and sensor technology for pharmaceutical research.
Drug discovery in the era of Multi-omics and spatial cytometry: Exploration of the latest multi-parameter techniques and the analytical challenges of using multi-omics approaches to link the genome and proteome to cellular regulation and function.
We aim to bring together the research community working in the field of flow cytometry and imaging with interests in developing and applying the technology for pharmaceutical research. Join scientists from pharma, biotech, CROs and academia to hear talks given by speakers at the cutting edge of cytometry, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.
<< less

Pharmaceutical Flow Cytometry & Imaging 2021
The 7th biennial Pharmaceutical Flow Cytometry and Imaging meeting will be held at GlaxoSmithKline, Stevenage, UK. Flow cytometry and imaging are two powerful technology platforms that enable high-content analysis of physiologically-relevant cell systems more >>